Clarivate Sheds Life Sciences Division in $600 Million Deal

The divestiture includes $500 million in cash at closing, with an additional $25 million deferred and a $75 million seller note. Chief Executive Officer Matti Shem Tov described the sale as a core component of the company’s Value Creation Plan, intended to optimize business operations and sharpen focus on its remaining segments. By shedding the life sciences unit, Clarivate expects to improve its revenue mix and reduce capital intensity.

Chief Financial Officer Jonathan Collins noted that proceeds from the sale will be directed toward aggressive debt reduction. While the company will record a non-cash goodwill impairment of roughly $225 to $250 million on the segment, it has reaffirmed its full-year 2026 financial outlook. Following the transition, Clarivate will operate as a leaner entity, concentrating resources on its core Academia & Government and Intellectual Property businesses.